The chronic thromboembolic pulmonary hypertension is the so-called WHO group 4 of mulmonal types of hypertension, a sub-group that consists of different underlying diseases. Foremost here, however, is chronic thromboembolic pulmonary hypertension on the basis of recurring pulmonary embolisms. This short presentation makes the CTEPH treatment algorithm a subject of discussion as well as the CHEST-study and elucidates the Hybrid-BPA with the help of videos.
Treatment of CTEPH
Head, Pulmonary Hypertension, University Clinic Giessen, Professor for Pulmonary Vascular Medicine, University Giessen Head of Pneumology, Bad Nauheim, University Clinic Giessen and Marburg GmbH, Kerckhoff Klinik Bad Nauheim, Department of Medicine, Imperial College London, Excellence Cluster Cardio-Pulmonary System (ECCPS), German Center for Lung Research (DZL)
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.